EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

Louis Calméjane iD, Catherine Reenaers, Claire Gay, Aurélien Amiot, Alexandre Nuzzo, Lucine Vuitton, Calina Atanasiu, Carmen Stefanescu, Romain Altwegg, Lucas Guillo, Mélanie Serrero, Guillaume Bouguen und 22 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70203 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Louis Calméjane und 33 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de Médecine, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Vedolizumab has become the preferred first‐line advanced therapy in ulcerative colitis (UC). However, the optimal second‐line treatment following vedolizumab failure remains unclear. We aimed to evaluate the effectiveness and safety of second‐line therapies after first‐line vedolizumab.

Methods

We conducted a multicenter retrospective study including UC patients from 31 centers who received infliximab (IFX), subcutaneous (SC) anti‐TNFs, or ustekinumab after vedolizumab failure. The primary endpoint was steroid‐free clinical remission (SFCR) at week 14. Predictors of remission were identified using multivariate logistic regression.

Results

Among 196 patients, 99 received IFX, 27 anti‐TNF SC, and 70 ustekinumab. At week 14, SFCR was achieved in 78 patients (39.8%): 38 (38.4%) with IFX, 8 (29.6%) with anti‐TNF SC, and 32 (45.7%) with ustekinumab, with no significant difference between groups ( p = 0.32). Median treatment persistence ranged from 8 to 9.2 months. Baseline corticosteroid use was associated with lower odds of SFCR (OR = 0.37, 95% CI [0.18–0.73]). Adverse events occurred in 15.8% of patients, including 12.2% serious events. Overall adverse events were less frequent with ustekinumab than with IFX (10.0% vs. 24.2%, p = 0.02), while serious events were comparable (5.7% vs. 16.1%, p = 0.08). Discontinuation due to adverse events was more frequent with IFX (12.1%) and anti‐TNF SC (14.8%) than with ustekinumab (2.9%, p = 0.045 and 0.049).

Conclusion

In UC patients failing vedolizumab, second‐line IFX, anti‐TNF SC, and ustekinumab showed similar effectiveness and persistence. Infliximab remains a robust option for rapid control in high inflammatory burden, whereas ustekinumab may be preferred for its superior safety profile in high‐risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedColitis, UlcerativeGastrointestinal AgentsAdultFemaleHumansMaleMiddle AgedInfliximabRemission InductionRetrospective StudiesTreatment FailureTreatment OutcomeTumor Necrosis Factor-alphaUstekinumab

Stichwörter der Autor:innen

anti‐TNFbiologicsinfliximabtreatment sequencingulcerative colitisustekinumabvedolizumab

Substanzen

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsInfliximabTumor Necrosis Factor-alphaUstekinumabvedolizumab

Autor:innen und Institutionen

  • Faculté de Médecine, Université Paris Cité, Paris, France.
  • Gastroenterology Department, CHU Sart-Tilman, Liège, Belgium.
  • Department of Gastroenterology, CHU de Lyon, Lyon-Sud Hospital, Pierre-Benite, France and INSERM U1111-CIRI, Lyon, France.
  • Department of Gastroenterology, Hôpitaux Universitaires Bicêtre, AP-HP, Université Paris Saclay, Le Kremlin Bicêtre, France.
  • Department of Gastroenterology, IBD and Intestinal Failure, Intestinal Stroke Center, AP-HP Hôpital Beaujon, Clichy, France.
  • Department of Gastroenterology, Besancon University Hospital, Besancon, France.

ORCID-Profile: Louis Calméjane, Mathurin Fumery, Benoît Coffin, David Laharie, Mathieu Uzzan

Zitieren

APA

Calméjane, L., Reenaers, C., Gay, C., Amiot, A., Nuzzo, A., Vuitton, L., Atanasiu, C., Stefanescu, C., Altwegg, R., Guillo, L., Serrero, M., Bouguen, G., Nachury, M., Le Cosquer, G., Roblin, X., Abitbol, V., Hammoudi, N., Simon, M., Fumery, M., …, & GETAID‐AFTER‐VEDO Study Group (2026). Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70203

Vancouver

Calméjane L, Reenaers C, Gay C, Amiot A, Nuzzo A, Vuitton L, et al. Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70203

BibTeX
@article{Calmjane2026,
  author = {Calméjane, Louis and Reenaers, Catherine and Gay, Claire and Amiot, Aurélien and Nuzzo, Alexandre and Vuitton, Lucine and Atanasiu, Calina and Stefanescu, Carmen and Altwegg, Romain and Guillo, Lucas and Serrero, Mélanie and Bouguen, Guillaume and Nachury, Maria and Le Cosquer, Guillaume and Roblin, Xavier and Abitbol, Vered and Hammoudi, Nassim and Simon, Marion and Fumery, Mathurin and Savoye, Guillaume and Benezech, Alban and Cavicchi, Maryan and Charkaoui, Maeva and Buisson, Anthony and Caron, Bénédicte and Coffin, Benoît and Geyl, Sophie and Goutorbe, Félix and Hupé, Marianne and Vidon, Mathias and Laharie, David and Kirchgesner, Julien and Uzzan, Mathieu and GETAID‐AFTER‐VEDO Study Group, GETAID‐AFTER‐VEDO Study Group},
  title = {Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70203}
}
Kostenlos starten →